Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers

Cell Reports

Volumn 11, Issue 10, 2015, Pages 1604-1613

  Pritchard, Laura K ^a   Vasiljevic, Snezana ^a   Ozorowski, Gabriel ^b   Seabright, Gemma E ^a   Cupo, Albert ^c   Ringe, Rajesh ^c   Kim, Helen J ^b   Sanders, Rogier W ^c,d   Doores, Katie J ^e   Burton, Dennis R ^f,g   Wilson, Ian A ^b   Ward, Andrew B ^b   Moore, John P ^c   Crispin, Max ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e GUY S HOSPITAL   (United Kingdom)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

^g HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; NEUTRALIZING ANTIBODY; POLYSACCHARIDE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHILIC INTERACTION CHROMATOGRAPHY; IMMUNOGENICITY; LYMPHOID CELL; MOLECULAR RECOGNITION; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; ANIMAL; CHEMISTRY; CHO CELL LINE; CRICETULUS; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR MODEL; PROTEIN QUATERNARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MAMMALIA;

ANIMALS; ANTIBODIES, NEUTRALIZING; CHO CELLS; CRICETULUS; GLYCOSYLATION; HEK293 CELLS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MODELS, MOLECULAR; POLYSACCHARIDES; PROTEIN STRUCTURE, QUATERNARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84937641486     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.05.017     Document Type: Article

References (54)

1. Blattner C., Lee J.H., Sliepen K., Derking R., Falkowska E., de la Peña A.T., Cupo A., Julien J.-P., van Gils M., Lee P.S., et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 2014, 40:669-680.
2. Bonomelli C., Doores K.J., Dunlop D.C., Thaney V., Dwek R.A., Burton D.R., Crispin M., Scanlan C.N. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS ONE 2011, 6:e23521.
3. Burton D.R., Ahmed R., Barouch D.H., Butera S.T., Crotty S., Godzik A., Kaufmann D.E., McElrath M.J., Nussenzweig M.C., Pulendran B., et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 2012, 12:396-407.
4. Calarese D.A., Scanlan C.N., Zwick M.B., Deechongkit S., Mimura Y., Kunert R., Zhu P., Wormald M.R., Stanfield R.L., Roux K.H., et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003, 300:2065-2071.
5. Chung N.P., Matthews K., Kim H.J., Ketas T.J., Golabek M., de Los Reyes K., Korzun J., Yasmeen A., Sanders R.W., Klasse P.J., et al. Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies. Retrovirology 2014, 11:33.
6. Crispin M., Bowden T.A. Antibodies expose multiple weaknesses in the glycan shield of HIV. Nat. Struct. Mol. Biol. 2013, 20:771-772.
7. Crooks E.T., Tong T., Osawa K., Binley J.M. Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected. J. Virol. 2011, 85:5825-5839.
8. Doores K.J., Bonomelli C., Harvey D.J., Vasiljevic S., Dwek R.A., Burton D.R., Crispin M., Scanlan C.N. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc. Natl. Acad. Sci. USA 2010, 107:13800-13805.
9. Dunlop D.C., Bonomelli C., Mansab F., Vasiljevic S., Doores K.J., Wormald M.R., Palma A.S., Feizi T., Harvey D.J., Dwek R.A., et al. Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans. Glycobiology 2010, 20:812-823.
10. Falkowska E., Le K.M., Ramos A., Doores K.J., Lee J.H., Blattner C., Ramirez A., Derking R., van Gils M.J., Liang C.-H., et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 2014, 40:657-668.
11. Feinberg H., Mitchell D.A., Drickamer K., Weis W.I. Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 2001, 294:2163-2166.
12. Garces F., Sok D., Kong L., McBride R., Kim H.J., Saye-Francisco K.F., Julien J.-P., Hua Y., Cupo A., Moore J.P., et al. Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell 2014, 159:69-79.
13. Geijtenbeek T.B., Torensma R., van Vliet S.J., van Duijnhoven G.C., Adema G.J., van Kooyk Y., Figdor C.G. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000, 100:575-585.
14. Georgiev I.S., Joyce M.G., Yang Y., Sastry M., Zhang B., Baxa U., Chen R.E., Druz A., Lees C.R., Narpala S., et al. Single-chain soluble BG505.SOSIP gp140 trimers as structural and antigenic mimics of mature closed HIV-1. Env. J. Virol. 2015, 89:5318-5329.
15. Go E.P., Liao H.-X., Alam S.M., Hua D., Haynes B.F., Desaire H. Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins. J. Proteome Res. 2013, 12:1223-1234.
16. Go E.P., Hua D., Desaire H. Glycosylation and disulfide bond analysis of transiently and stably expressed clade C HIV-1 gp140 trimers in 293T cells identifies disulfide heterogeneity present in both proteins and differences in O-linked glycosylation. J. Proteome Res. 2014, 13:4012-4027.
17. Guttman M., Garcia N.K., Cupo A., Matsui T., Julien J.-P., Sanders R.W., Wilson I.A., Moore J.P., Lee K.K. CD4-induced activation in a soluble HIV-1 Env trimer. Structure 2014, 22:974-984.
18. Hessell A.J., Rakasz E.G., Poignard P., Hangartner L., Landucci G., Forthal D.N., Koff W.C., Watkins D.I., Burton D.R. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009, 5:e1000433.
19. Huang J., Kang B.H., Pancera M., Lee J.H., Tong T., Feng Y., Imamichi H., Georgiev I.S., Chuang G.Y., Druz A., et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 2014, 515:138-142.
20. Julien J.-P., Cupo A., Sok D., Stanfield R.L., Lyumkis D., Deller M.C., Klasse P.-J., Burton D.R., Sanders R.W., Moore J.P., et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1477-1483.
21. Kong L., Lee J.H., Doores K.J., Murin C.D., Julien J.P., McBride R., Liu Y., Marozsan A., Cupo A., Klasse P.J., et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 2013, 20:796-803.
22. Kovacs J.M., Nkolola J.P., Peng H., Cheung A., Perry J., Miller C.A., Seaman M.S., Barouch D.H., Chen B. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc. Natl. Acad. Sci. USA 2012, 109:12111-12116.
23. Lasky L.A., Groopman J.E., Fennie C.W., Benz P.M., Capon D.J., Dowbenko D.J., Nakamura G.R., Nunes W.M., Renz M.E., Berman P.W. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science 1986, 233:209-212.
24. Leonard C.K., Spellman M.W., Riddle L., Harris R.J., Thomas J.N., Gregory T.J. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 1990, 265:10373-10382.
25. Lewis D.J., Fraser C.A., Mahmoud A.N., Wiggins R.C., Woodrow M., Cope A., Cai C., Giemza R., Jeffs S.A., Manoussaka M., et al. Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally. PLoS ONE 2011, 6:e25165.
26. Lewis D.J.M., Wang Y., Huo Z., Giemza R., Babaahmady K., Rahman D., Shattock R.J., Singh M., Lehner T. Effect of vaginal immunization with HIVgp140 and HSP70 on HIV-1 replication and innate and T cell adaptive immunity in women. J. Virol. 2014, 88:11648-11657.
27. Liu J., Bartesaghi A., Borgnia M.J., Sapiro G., Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008, 455:109-113.
28. Lyumkis D., Julien J.-P., de Val N., Cupo A., Potter C.S., Klasse P.-J., Burton D.R., Sanders R.W., Moore J.P., Carragher B., et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1484-1490.
29. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 2000, 6:207-210.
30. McLellan J.S., Pancera M., Carrico C., Gorman J., Julien J.-P., Khayat R., Louder R., Pejchal R., Sastry M., Dai K., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480:336-343.
31. Moldt B., Rakasz E.G., Schultz N., Chan-Hui P.-Y., Swiderek K., Weisgrau K.L., Piaskowski S.M., Bergman Z., Watkins D.I., Poignard P., Burton D.R. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. USA 2012, 109:18921-18925.
32. Moscoso C.G., Xing L., Hui J., Hu J., Kalkhoran M.B., Yenigun O.M., Sun Y., Paavolainen L., Martin L., Vahlne A., et al. Trimeric HIV Env provides epitope occlusion mediated by hypervariable loops. Sci. Rep. 2014, 4:7025.
33. Mouquet H., Scharf L., Euler Z., Liu Y., Eden C., Scheid J.F., Halper-Stromberg A., Gnanapragasam P.N.P., Spencer D.I.R., Seaman M.S., et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl. Acad. Sci. USA 2012, 109:E3268-E3277.
34. Murin C.D., Julien J.-P., Sok D., Stanfield R.L., Khayat R., Cupo A., Moore J.P., Burton D.R., Wilson I.A., Ward A.B. Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy. J. Virol. 2014, 88:10177-10188.
35. Neville D.C.A., Dwek R.A., Butters T.D. Development of a single column method for the separation of lipid- and protein-derived oligosaccharides. J. Proteome Res. 2009, 8:681-687.
36. Nkolola J.P., Peng H., Settembre E.C., Freeman M., Grandpre L.E., Devoy C., Lynch D.M., La Porte A., Simmons N.L., Bradley R., et al. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. J. Virol. 2010, 84:3270-3279.
37. Ogura T., Iwasaki K., Sato C. Topology representing network enables highly accurate classification of protein images taken by cryo electron-microscope without masking. J. Struct. Biol. 2003, 143:185-200.
38. Pabst M., Chang M., Stadlmann J., Altmann F. Glycan profiles of the 27 N-glycosylation sites of the HIV envelope protein CN54gp140. Biol. Chem. 2012, 393:719-730.
39. Pancera M., Shahzad-Ul-Hussan S., Doria-Rose N.A., McLellan J.S., Bailer R.T., Dai K., Loesgen S., Louder M.K., Staupe R.P., Yang Y., et al. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat. Struct. Mol. Biol. 2013, 20:804-813.
40. Pancera M., Zhou T., Druz A., Georgiev I.S., Soto C., Gorman J., Huang J., Acharya P., Chuang G.-Y., Ofek G., et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 2014, 514:455-461.
41. Pejchal R., Doores K.J., Walker L.M., Khayat R., Huang P.-S., Wang S.-K., Stanfield R.L., Julien J.-P., Ramos A., Crispin M., et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011, 334:1097-1103.
42. Pugach P., Ozorowski G., Cupo A., Ringe R., Yasmeen A., de Val N., Derking R., Kim H.J., Korzun J., Golabek M., et al. A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. J. Virol. 2015, 89:3380-3395.
43. Raska M., Takahashi K., Czernekova L., Zachova K., Hall S., Moldoveanu Z., Elliott M.C., Wilson L., Brown R., Jancova D., et al. Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J. Biol. Chem. 2010, 285:20860-20869.
44. Ringe R.P., Sanders R.W., Yasmeen A., Kim H.J., Lee J.H., Cupo A., Korzun J., Derking R., van Montfort T., Julien J.P., et al. Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc. Natl. Acad. Sci. USA 2013, 110:18256-18261.
45. Sanders R.W., Venturi M., Schiffner L., Kalyanaraman R., Katinger H., Lloyd K.O., Kwong P.D., Moore J.P. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 2002, 76:7293-7305.
46. Sanders R.W., Derking R., Cupo A., Julien J.-P., Yasmeen A., de Val N., Kim H.J., Blattner C., de la Peña A.T., Korzun J., et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 2013, 9:e1003618.
47. Scanlan C.N., Pantophlet R., Wormald M.R., Ollmann Saphire E., Stanfield R., Wilson I.A., Katinger H., Dwek R.A., Rudd P.M., Burton D.R. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1->2 mannose residues on the outer face of gp120. J. Virol. 2002, 76:7306-7321.
48. Scharf L., Scheid J.F., Lee J.H., West A.P., Chen C., Gao H., Gnanapragasam P.N.P., Mares R., Seaman M.S., Ward A.B., et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep. 2014, 7:785-795.
49. Schiffner T., Kong L., Duncan C.J., Back J.W., Benschop J.J., Shen X., Huang P.S., Stewart-Jones G.B., DeStefano J., Seaman M.S., et al. Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking. J. Virol. 2013, 87:10163-10172.
50. Tran K., Poulsen C., Guenaga J., de Val N., Wilson R., Sundling C., Li Y., Stanfield R.L., Wilson I.A., Ward A.B., et al. Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc. Natl. Acad. Sci. USA 2014, 111:E738-E747.
51. Voss N.R., Yoshioka C.K., Radermacher M., Potter C.S., Carragher B. DoG Picker and TiltPicker: software tools to facilitate particle selection in single particle electron microscopy. J. Struct. Biol. 2009, 166:205-213.
52. Walker L.M., Phogat S.K., Chan-Hui P.-Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289. Protocol G Principal Investigators.
53. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.-P., Wang S.-K., Ramos A., Chan-Hui P.-Y., Moyle M., et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470. Protocol G Principal Investigators.
54. Yasmeen A., Ringe R., Derking R., Cupo A., Julien J.-P., Burton D.R., Ward A.B., Wilson I.A., Sanders R.W., Moore J.P., Klasse P.J. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology 2014, 11:41.